History | Avelumab for untreated metastatic Merkel cell carcinoma | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 139 KB)

Published:

21 April 2021
Register of interests (PDF 143 KB)

Published:

21 April 2021

Final draft guidance

Final draft guidance
Final appraisal document (PDF 188 KB)

Published:

17 March 2021
Committee papers (PDF 5.67 MB)

Published:

17 March 2021
Public committee slides (PDF 1.02 MB)

Published:

17 March 2021

Invitation to participate

Final scope (PDF 174 KB)

Published:

04 February 2020
Final stakeholder list (PDF 188 KB)

Published:

04 February 2020

Final draft guidance: TA517

Final appraisal document - TA517 (PDF 430 KB)

Published:

01 March 2018
Final appraisal document - managed access agreement - TA517 (PDF 498 KB)

Published:

01 March 2018
Committee papers (FAD) - TA517 (PDF 2.26 MB)

Published:

01 March 2018
Public committee slides - TA517 (PDF 544 KB)

Published:

01 March 2018
Final appraisal document - equality impact assessment - TA517 (PDF 235 KB)

Published:

11 April 2018

Draft guidance: TA517

Appraisal consultation document (PDF version) - TA517 (PDF 420 KB)

Published:

27 November 2017
Committee papers (ACD) - TA517 (PDF 11.14 MB)

Published:

22 February 2018
Public committee slides (clinical) - TA517 (PDF 423 KB)

Published:

27 November 2017
Public committee slides (cost) - TA517 (PDF 425 KB)

Published:

27 November 2017

Invitation to participate

Final scope - TA517 (PDF 252 KB)

Published:

18 April 2017
Final stakeholder list - TA517 (PDF 262 KB)

Published:

18 April 2017
NICE's response to comments on the draft scope and provisional stakeholder list - TA517 (PDF 308 KB)

Published:

18 April 2017
Equality impact assessment (Scoping) - TA517 (PDF 174 KB)

Published:

25 April 2017